Prescription Drugs · Cardiometabolic Therapeutics
Eli Lilly and Company: Products & infrastructure
Eli Lilly and Company has 6 apps in the stores: 6,776 ratings and 101k+ downloads on Google Play.
Data updated Nov 22, 2026 · Back to the company report
Products
Eli Lilly and Company has 6 apps in the stores: 6,776 ratings and 101k+ downloads on Google Play.
6.8kStore ratings
101k+Google Play downloads
6Apps
$887.9Mpaid to US doctors in 2025
FDA approvalsnew drugs, biologics and high-risk devices, per Drugs@FDA and PMA · and 38 more records
Jul 2024
Dec 2021
Taltz
EU authorisation (EMA) · EMEA/H/C/003943 · ixekizumab · Psoriasis;Arthritis, Psoriatic;Axial Spondyloarthritis;Arthritis, Juvenile
Apr 2016
Portrazza
Biologic (BLA) · BLA125547 · necitumumab · intra-articular, intramuscular, intravitreal
Nov 2015
Nov 2010
May 2009
Jun 2008
Sep 2007
EU clinical trialsthe trials it sponsors, per the EU's CTIS register
A study of LY3971297 in Participants with Heart Failure
Human Pharmacology (Phase I)- Other · Heart Failure, Diastolic, Heart Failure, Systolic, Heart Fa… · Netherlands, Romania
Nov 2026
A Study of LY4152199 in Participants with Previously Treated B-cell Malignancies (BAF_FRontier-1)
Human Pharmacology (Phase I)- First administration to humans · B-Cell cancers · Italy, France, Denmark, Poland, Spain, Germany
Nov 2026
J2A-MC-GZVA:A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Onc…
Therapeutic confirmatory (Phase III) · Prehypertension, Prediabetic State, Overweight, Obesity, Ab… · Czechia, Germany, Spain
Oct 2026
J3R-MC-YDAS:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of O…
Therapeutic confirmatory (Phase III) · Cardiovascular Diseases, Diabetes Mellitus, Type 2, Overwei… · Spain, Poland, France, Italy, Germany, Czechia, R…
Oct 2026
A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participant…
Human Pharmacology (Phase I)- Other · Amyotrophic Lateral Sclerosis · Netherlands, Belgium, Germany, Spain
Sep 2026
J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-…
Therapeutic confirmatory (Phase III) · Diabetes Mellitus, Type 2 · Italy, Spain, Belgium
Sep 2026
Payments to US doctorsCMS Open Payments - the maker's totals, no recipient
$887.9M
$716M
$633.9M
Compensation For Services Other Than Consulting, Including S
a kind of payment, 2025
$34.5M
$8.9M
$8.4M
$9.8M
$9.2M
$8.8M
Clinical trialsthe studies it sponsors or works on, per ClinicalTrials.gov · and 2,343 more records
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
phase 2 · under way · 161 participants · Urinary Bladder Neoplasms; Urologic Neoplasms; Receptor, Fibroblast Growth Fact…
Dec 2026
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants
phase 1 · under way · 64 participants · Healthy Participants
Dec 2026
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiova…
phase 3 · under way · 3,000 participants · Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2
Dec 2026
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
phase 1 · under way · 370 participants · Endometrial Neoplasms; Ovarian Neoplasms; Neoplasms, Germ Cell and Embryonal; C…
Dec 2026
A Study of LY3981314 in Participants With Autoimmune Hepatitis
phase 1 · under way · 12 participants · Hepatitis Autoimmune Disease; Hepatitis
Dec 2026
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Proble…
phase 3 · under way · 192 participants · Obesity; Overweight
Dec 2026
A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Brea…
phase 2 · under way · 120 participants · Breast Neoplasms
Dec 2026
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
phase 3 · under way · 2,115 participants · Obesity
Dec 2026
FDA 510(k) clearancesmedical devices cleared for the US market
Sep 2022
Dec 2016
Jun 2016
Dec 2015
Jun 2015
Aug 2010
Jan 2007
Apr 2006
Apps
App Store · 5,584 ratings · Medical · Eli Lilly and Company
4.8 ★
Google Play · 1,180 ratings · 100k+ downloads · Eli Lilly and Company
4.7 ★
Google Play · 500+ downloads · Eli Lilly and Company
App Store · 6 ratings · Business · Eli Lilly and Company
3.7 ★
App Store · 5 ratings · Business · Eli Lilly and Company
5.0 ★
App Store · 1 ratings · Health & Fitness · Eli Lilly and Company
1.0 ★
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Infrastructure
Eli Lilly and Company holds 5 MW of generating capacity in 1 US power plants (EIA-860, 2025).
5 MWUS generating capacity
1US power plants
Power plantsEIA-860
Lilly Technical Center
IN · Petroleum Liquids · operator Eli Lilly and Company · eia.gov ↗
5 MW
Power plants: EIA-860 - the operating utility holds a solely owned generator, each owner its percent of a jointly owned one; nameplate capacity of operable generators; each plant links its EIA page.
